Search results for "Liver function"

showing 10 items of 176 documents

Add-On Peginterferon Alfa-2a Significantly Reduces HBsAg Levels in HBeAg-Negative, Genotype D Chronic Hepatitis B Patients Fully Suppressed on Nucleo…

2016

23 (36%) cases, respectively. Ribavirin (RBV) was used in 35% and 65% of the patients receiving SOF and DCV, respectively. Most of the patients were male (72%) and genotype 1b (81%). Median age was 59 years. Median baseline MELD and Child–Pugh (CPT) scores were 9 and 6, respectively. Among the patients with cirrhosis, 47% were CPT B/C. Tacrolimus was the immunosuppressant used in the majority of the patients (69%). At the beginning of therapy, 20 patients had ascites and 3 had hepatic encephalopathy (HE). Thirty-four patients completed the treatment course and 30 are still on therapy. End of treatment (EOT) response was 88% (30/34) and SVR12 was 83% (25/30). In patients receiving SMV+DCV±RB…

0301 basic medicinemedicine.medical_specialtyHBsAgCirrhosisAnemiaGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAscitesmedicineHepatic encephalopathyHepatologybusiness.industryRibavirinmedicine.disease030104 developmental biologychemistryImmunology030211 gastroenterology & hepatologyLiver functionmedicine.symptombusinessPeginterferon alfa-2amedicine.drugJournal of Hepatology
researchProduct

Safflower Yellow and Its Main Component HSYA Alleviate Diet-Induced Obesity in Mice: Possible Involvement of the Increased Antioxidant Enzymes in Liv…

2020

PurposeOxidative stress plays an important role in the pathogenesis of obesity and its associated disorders. Safflower yellow (SY) and hydroxysafflor yellow A (HSYA), the natural compounds isolated from Carthamus tinctorius L., has been found to possess antioxidative and anti-obesity properties. The purpose of the present study is to investigate whether SY and its main component HSYA alleviate obesity by the antioxidant effects.MethodsDiet-induced obese (DIO) mice were treated with 200 mg/kg/d SY or HSYA for 10 weeks. Body weight, fat mass, serum biochemical parameters and superoxide dismutase (SOD) activities were measured. Glucose and insulin tolerance tests were performed. The expression…

0301 basic medicinemedicine.medical_specialtyobesityAntioxidantmedicine.medical_treatmentAdipose tissueCarbohydrate metabolismmedicine.disease_causeliverSuperoxide dismutase03 medical and health sciences0302 clinical medicineantioxidant enzymesInternal medicinemedicinePharmacology (medical)Original ResearchPharmacologysafflower yellow (SY)biologyChemistryCarthamuslcsh:RM1-950Metabolismbiology.organism_classificationadipose tissue030104 developmental biologyEndocrinologylcsh:Therapeutics. Pharmacology030220 oncology & carcinogenesishydroxysafflor yellow A (HSYA)biology.proteinLiver functionOxidative stressFrontiers in Pharmacology
researchProduct

Pattern of macrovascular invasion in hepatocellular carcinoma

2021

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed …

Ablation TechniquesMaleRegistrieCirrhosisClinical BiochemistryMesenteric Veinloco-regional treatment030204 cardiovascular system & hematologyBiochemistryGastroenterologysurgeryAntineoplastic AgentLiver disease0302 clinical medicineNon-alcoholic Fatty Liver Diseasecirrhosis; hepatocellular carcinoma; loco-regional treatment; portal vein thrombosis; surgery; transplantationAscitesAblation Techniqueportal vein thrombosisRegistries030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaPortal VeinLiver DiseasesLiver NeoplasmsAsciteshepatocellular carcinomaGeneral MedicineMiddle AgedSorafenibPrognosisHepatitis BAlcoholicHepatitis CTumor BurdenSurvival RateItalyLiver NeoplasmHepatocellular carcinomaAsciteFemalemedicine.symptomLiver cancerHumanmedicine.medical_specialtyCarcinoma HepatocellularPrognosiAntineoplastic AgentsEnd Stage Liver Disease03 medical and health sciencesMesenteric VeinsHepatitis B ChronicInternal medicinemedicineHumansHepatectomyNeoplasm Invasivenessportal vein thrombosiLiver Diseases AlcoholicAgedNeoplasm Invasivene...Performance statusbusiness.industrycirrhosisCarcinomaSettore MED/09 - MEDICINA INTERNAPatient AcuityHepatocellularHepatitis C Chronicmedicine.diseaseLiver TransplantationTransplantationLiver functionbusinesscirrhositransplantationEuropean Journal of Clinical Investigation
researchProduct

Disposition of azapropazone in chronic renal and hepatic failure.

1981

The disposition of azapropazone 600 mg i.v. was investigated in 6 healthy subjects, 13 patients with cirrhosis and 8 patients with renal failure. In healthy subjects the elimination half-life was 12.2±2.1 h (mean ± SD), the volume of distribution 10.6±3.31 and the total clearance was 597±135 ml·h−1. Renal clearance accounted for about 62% of the total clearance. The free fraction of azapropazone in the plasma was 0.0045±0.0006. The patients with cirrhosis were divided into Group I with modest and Group II with severe impairment of liver function. In Group I the total clearance of azapropazone was not significantly different from that in healthy subjects. There was a 2.5-fold increase in its…

AdultApazoneMalemedicine.medical_specialtyCirrhosisUrologyRenal functionchemistry.chemical_compoundPharmacokineticsInternal medicineMedicineHumansPharmacology (medical)AzapropazonePharmacologyVolume of distributionCreatininebusiness.industryTriazinesLiver DiseasesGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologychemistryFree fractionCreatinineKidney Failure ChronicLiver functionbusinessmedicine.drugHalf-LifeEuropean journal of clinical pharmacology
researchProduct

Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease

2015

Background/Aims We assessed whether obstructive sleep apnea (OSA) and nocturnal hypoxemia are associated with severity of liver fibrosis and carotid atherosclerosis in patients with biopsy-proven NAFLD and low prevalence of morbid obesity. Secondary aim was to explore the association of OSA and hypoxemia with NASH and severity of liver pathological changes. Methods Consecutive patients (n = 126) with chronically elevated ALT and NAFLD underwent STOP-BANG questionnaire to estimate OSA risk and ultrasonographic carotid assessment. In patients accepting to perform cardiorespiratory polygraphy (PG, n = 50), OSA was defined as an apnea/hypopnea index ≥5. A carotid atherosclerotic plaque was defi…

AdultCarotid Artery DiseasesLiver CirrhosisMalemedicine.medical_specialtyBiopsylcsh:MedicinePolysomnographySeverity of Illness IndexGastroenterologyLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsSurveys and QuestionnairesInternal medicineSeverity of illnessPrevalencemedicineHumansHypoxialcsh:ScienceAgedNAFLD OSAS ATHEROSCLEROSISSleep Apnea ObstructiveMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RFatty liverApneaSleep apneaMiddle AgedAtherosclerosismedicine.diseasePlaque Atheroscleroticrespiratory tract diseases3. Good healthObstructive sleep apneaEndocrinologyFemalelcsh:Qmedicine.symptombusinessLiver function testsHypopneaResearch ArticlePLOS ONE
researchProduct

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants

2003

Abstract A live attenuated human rotavirus (HRV) vaccine, strain RIX4414, was tested sequentially in adults, previously infected toddlers, and previously uninfected infants. A single dose was given to adults and toddlers and found well tolerated. Next, a dose ranging (three different viral concentrations) safety and immunogenicity study was conducted in rotavirus IgA antibody negative infants (N=192), who received two doses of RIX4414 vaccine or placebo at 2 and 4 months of age. No side effects were seen after vaccination. Specifically, administration of RIX4414 vaccine was not temporally associated with fever, diarrhea, or increase in liver transaminases. Rotavirus IgA seroconversion range…

AdultDiarrheaMaleAdolescentDose-Response Relationship ImmunologicReoviridaeVaccines Attenuatedmedicine.disease_causeRotavirus InfectionsVirusFecesDouble-Blind MethodLiver Function TestsRotavirusmedicineHumansCloning MolecularSeroconversionGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryImmunogenicityRotavirus VaccinesPublic Health Environmental and Occupational HealthInfantbiology.organism_classificationVirologyImmunoglobulin AVaccinationTiterDiarrheaInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalemedicine.symptombusinessVaccine
researchProduct

Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected pat…

2018

Purpose: We aimed to assess the diagnostic reliability of two indirect biomarkers, APRI and FIB-4, for the staging of liver fibrosis using transient elastography (TE) as reference standard, among HIV/HCV co-infected and HCV mono-infected patients. Methods: This is an observational, retrospective study on subjects who had access to the RESIST HCV from October 2013 to December 2016, a regional network encompassing 22 hospitals and academic centers throughout Sicily. Sensitivity, specificity and diagnostic accuracy of indirect biomarkers for liver stiffness measurement (LSM) < 9.5 kPa (significant fibrosis) and LSM ≥ 12.5 kPa (cirrhosis) were determined by receiver operator characteristics …

AdultLiver CirrhosisMale0301 basic medicineMicrobiology (medical)medicine.medical_specialtyTransient elastographyCirrhosis030106 microbiologyHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusmedicine.disease_causeGastroenterology03 medical and health sciences0302 clinical medicineLiver Function TestsLiver stiffnessInternal medicineNoninvasive biomarkermedicineHumansAspartate Aminotransferases030212 general & internal medicineSicilyRetrospective StudiesAPRIReceiver operating characteristicCoinfectionbusiness.industryReproducibility of ResultsHIVvirus diseasesRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesInfectious DiseasesHCVFIB-4Elasticity Imaging TechniquesFemaleUltrasonographyTransient elastographybusinessBiomarkersSignificant fibrosisInfection
researchProduct

Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa

2017

Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early experiences from a pilot program for treatment of CHB in Ethiopia. Adults (≥18 years) with CHB were included in a cohort study at St. Paul’s Hospital Millennium Medical College, Addis Ababa, from February 2015. The baseline assessment included liver function tests, viral markers and transient elastography (Fibroscan 402, Echosense, France). Logistic regression models were used to identify predictors of fibrosis. Tenofovir disoproxil fumarate (TDF) was initiated based on the European Association for the Study of the Liver (EASL) criteria, with some modifications. The initial 300 patients …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyCirrhosisPilot ProjectsAntiviral therapyAntiviral Agentslcsh:Infectious and parasitic diseasesCohort StudiesYoung Adult03 medical and health sciencesHepatitis B Chronic0302 clinical medicinePregnancyInterquartile rangeInternal medicinemedicineHumanslcsh:RC109-216Hepatitis B e Antigens030212 general & internal medicinePregnancy Complications InfectiousTenofovirAIDS-Related Opportunistic Infectionsmedicine.diagnostic_testCoinfectionbusiness.industryAlanine TransaminaseMiddle AgedViral LoadHepatitis Bmedicine.diseaseResource-limited settingsInfectious DiseasesHBeAgAfricaImmunologyFemale030211 gastroenterology & hepatologyEthiopiaTransient elastographyLiver function testsbusinessViral loadBiomarkersResearch ArticleCohort study
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Circulating, intercellular adhesion molecule-1 in patients with hepatocellular carcinoma

1997

Intercellular adhesion molecule-1 (ICAM-1) is thought to play an important role in cellular immunological reactions. Expression can be induced by inflammatory cytokines in a wide variety of cells, including hepatocytes.To compare the behaviour of ICAM-1 in liver diseases.We assayed serum ICAM-1 (sICAM-1) in patients with hepatocellular carcinoma-associated liver cirrhosis, and compared them with a group of cirrhotic patients and controls. sICAM-1 values were also correlated with some biochemical parameters of liver function. Moreover, immunohistochemical localization of ICAM-1 was performed on liver tissue sections of patients with hepatocellular carcinoma, liver cirrhosis and a sample of n…

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyCarcinoma HepatocellularCirrhosisIntercellular Adhesion Molecule-1Chronic liver diseaseLiver diseasemedicineCarcinomaHumansEndotheliumAgedHepatologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyAlanine TransaminaseBilirubingamma-GlutamyltransferaseMiddle AgedAlkaline PhosphataseIntercellular Adhesion Molecule-1medicine.diseaseImmunohistochemistryHepatocellular carcinomaFemalealpha-FetoproteinsLiver functionLiver function testsbusiness
researchProduct